Sign In
Buy MDGL
$512.88
+7.13 (+1.41%)
At Close: Jun 22, 2026
Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results
07:00am, Thursday, 19'th Feb 2026
Fourth -quarter and full-year 2025 Rezdiffra ® (resmetirom) net sales of $321.1 million and $958.4 million, respectively As of year-end 2025 , more than 36,250 patients on Rezdiffra Built industry-le
Head-To-Head Review: Madrigal Pharmaceuticals (NASDAQ:MDGL) and Praxsyn (OTCMKTS:PXYN)
01:56am, Thursday, 19'th Feb 2026
Praxsyn (OTCMKTS:PXYN - Get Free Report) and Madrigal Pharmaceuticals (NASDAQ: MDGL - Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses bas
John Paulson's Strategic Moves: Madrigal Pharmaceuticals Inc. Sees a -3.09% Impact
06:08pm, Tuesday, 17'th Feb 2026
Insights into John Paulson (Trades, Portfolio)'s Fourth Quarter 2025 13F Filing John Paulson (Trades, Portfolio) recently submitted the 13F filing for the four
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 17'th Feb 2026
CONSHOHOCKEN, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associ
Madrigal Pharmaceuticals: What To Expect With Q4 Earnings Coming Thursday
08:15am, Tuesday, 17'th Feb 2026
Madrigal Pharmaceuticals is reiterated as a Strong Buy ahead of Q4 earnings, with a 12-month price target of $665, implying 43% upside. Rezdiffra's rapid commercialization and first-mover advantage in
What to Expect From These Drug/Biotech Players This Earnings Season?
03:16pm, Monday, 16'th Feb 2026
Let's take a closer look at what awaits Bausch Health, Amicus Therapeutics, BioMarin Pharmaceutical, Insmed and Madrigal Pharmaceuticals as they prepare to report quarterly results this week.
MDGL Strengthens MASH Franchise With New Genetic Approaches
11:41am, Thursday, 12'th Feb 2026
Madrigal inks $4.4B siRNA licensing deal with Ribo in $60M upfront pact, adding preclinical candidates, expanding MASH pipeline and eyeing FDA filings in 2026.
Madrigal (MDGL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:06am, Thursday, 12'th Feb 2026
Madrigal (MDGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ribo und Ribocure geben exklusive globale Lizenzvereinbarung mit Madrigal für neuartige siRNA-Therapeutika gegen MASH bekannt
05:47am, Thursday, 12'th Feb 2026
/PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) („Ribo") und ihre Tochtergesellschaft Ribocure Pharmaceuticals AB („Ribocure") gaben heute
/PRNewswire/ -- Suzhou Ribo Life Science Co, Ltd. (HKEX: 06938) (« Ribo ») et sa filiale Ribocure Pharmaceuticals AB (« Ribocure ») ont annoncé aujourd'hui
Baader Bank Aktiengesellschaft Invests $885,000 in Madrigal Pharmaceuticals, Inc. $MDGL
05:22am, Thursday, 12'th Feb 2026
Baader Bank Aktiengesellschaft purchased a new stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) during the undefined quarter, according to the company in its most recent Form 13F filin
MKKGY or MDGL: Which Is the Better Value Stock Right Now?
12:41pm, Wednesday, 11'th Feb 2026
Investors looking for stocks in the Medical - Drugs sector might want to consider either Merck KGaA (MKKGY) or Madrigal (MDGL). But which of these two stocks presents investors with the better value o
Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH
06:49am, Wednesday, 11'th Feb 2026
/PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today announced that they
Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH
06:25am, Wednesday, 11'th Feb 2026
SUZHOU, China and MÖLNDAL, Sweden, Feb. 11, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today announced
Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs
05:00am, Wednesday, 11'th Feb 2026
CONSHOHOCKEN, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-assoc
